Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 34Observational 2

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Breast 2Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Melanoma 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 79Blood Specimen Collection 67palbociclib 40Trastuzumab 34Drug Therapy 30Letrozole 29Anastrozole 27Radiotherapy 26Immunohistochemistry 26Mastectomy, Segmental 22Amplified Fragment Length Polymorphism Analysis 22Fulvestrant 21Biopsy 21exemestane 20Tamoxifen 20Interviews as Topic 20Gene Expression Profiling 20Magnetic Resonance Spectroscopy 19ribociclib 18Specimen Handling 18Mastectomy 18Neoadjuvant Therapy 17Paclitaxel 16High-Energy Shock Waves 16Capecitabine 16trastuzumab deruxtecan 15Mammography 15Psychiatric Rehabilitation 14Polymerase Chain Reaction 13Observation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × toripalimab × Breast × Clear all
NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Peking University Cancer Hospital & Institute

Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04234620 2020-01-21

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Shanghai Junshi Bioscience Co., Ltd.

Unknown
800 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡